Biogen (BIIB)
(Delayed Data from NSDQ)
$233.84 USD
+3.21 (1.39%)
Updated Jun 13, 2024 04:00 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 781 - 800 ( 805 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12, raises hopes of an improvement in growth prospects...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12 & Daclizumab, brings in a ray of hope for improvement in growth prospects...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on oral MS drug, BG-12, raises hopes of strong growth ahead....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Moderate Outperform : Encouraging data on oral MS drug, BG-12, raises hopes of strong growth ahead....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Disappointing sales performance by Tysabri & further competition expected from launch of Novartis?
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Tysabri?s poor off take & disappointing momentum in weekly additions raises.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Concern remains over likely implementation of price cuts in Europe in Q3 CY10 & lack of meaningful catalysts in 2010
Provider: FIRST GLOBAL
Analyst: THOMAS K